Original on Transparent.png


Our mission is to bring a broad range of potentially transformative medicines to patients in Greater China. 


We recently launched with a $72M Series A co-led by Cormorant Asset Management LP and  Hansoh Pharmaceutical Group Company Limited. Read the press-release here.

Our website will be up shortly.